126 related articles for article (PubMed ID: 29848992)
21. Loss of PTEN induces microtentacles through PI3K-independent activation of cofilin.
Vitolo MI; Boggs AE; Whipple RA; Yoon JR; Thompson K; Matrone MA; Cho EH; Balzer EM; Martin SS
Oncogene; 2013 Apr; 32(17):2200-10. PubMed ID: 22689060
[TBL] [Abstract][Full Text] [Related]
22. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
23. F-box protein 11 promotes the growth and metastasis of gastric cancer via PI3K/AKT pathway-mediated EMT.
Sun C; Tao Y; Gao Y; Xia Y; Liu Y; Wang G; Gu Y
Biomed Pharmacother; 2018 Feb; 98():416-423. PubMed ID: 29278851
[TBL] [Abstract][Full Text] [Related]
24. C-Jun drives melanoma progression in PTEN wild type melanoma cells.
Kappelmann-Fenzl M; Gebhard C; Matthies AO; Kuphal S; Rehli M; Bosserhoff AK
Cell Death Dis; 2019 Aug; 10(8):584. PubMed ID: 31378787
[TBL] [Abstract][Full Text] [Related]
25. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL.
Ma Y; Zhang P; Gao Y; Fan H; Zhang M; Wu J
Int J Clin Exp Pathol; 2015; 8(11):14875-84. PubMed ID: 26823817
[TBL] [Abstract][Full Text] [Related]
28. MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K/Akt pathway in breast cancer.
Li N; Miao Y; Shan Y; Liu B; Li Y; Zhao L; Jia L
Cell Death Dis; 2017 May; 8(5):e2796. PubMed ID: 28518139
[TBL] [Abstract][Full Text] [Related]
29. PTEN inhibition improves wound healing in lung epithelia through changes in cellular mechanics that enhance migration.
Mihai C; Bao S; Lai JP; Ghadiali SN; Knoell DL
Am J Physiol Lung Cell Mol Physiol; 2012 Feb; 302(3):L287-99. PubMed ID: 22037358
[TBL] [Abstract][Full Text] [Related]
30. Phosphatidylinositol 3-kinase (PI3K) signalling regulates insulin-like-growth factor binding protein-2 (IGFBP-2) production in human adipocytes.
Wilhelm F; Kässner F; Schmid G; Kratzsch J; Laner A; Wabitsch M; Körner A; Kiess W; Garten A
Growth Horm IGF Res; 2015 Jun; 25(3):115-20. PubMed ID: 25900365
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
Xia H; Ooi LL; Hui KM
Hepatology; 2013 Aug; 58(2):629-41. PubMed ID: 23471579
[TBL] [Abstract][Full Text] [Related]
32. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR
PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN.
Zhou K; Zhang T; Fan Y; Serick ; Du G; Wu P; Geng D
Tumour Biol; 2016 Oct; 37(10):13469-13477. PubMed ID: 27465551
[TBL] [Abstract][Full Text] [Related]
34. Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations.
Dan S; Okamura M; Seki M; Yamazaki K; Sugita H; Okui M; Mukai Y; Nishimura H; Asaka R; Nomura K; Ishikawa Y; Yamori T
Cancer Res; 2010 Jun; 70(12):4982-94. PubMed ID: 20530683
[TBL] [Abstract][Full Text] [Related]
35. PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.
Nozhat Z; Hedayati M
Mol Diagn Ther; 2016 Feb; 20(1):13-26. PubMed ID: 26597586
[TBL] [Abstract][Full Text] [Related]
36. Human immunodeficiency virus type 1 induces lytic cycle replication of Kaposi's-sarcoma-associated herpesvirus: role of Ras/c-Raf/MEK1/2, PI3K/AKT, and NF-κB signaling pathways.
Zhu X; Zhou F; Qin D; Zeng Y; Lv Z; Yao S; Lu C
J Mol Biol; 2011 Jul; 410(5):1035-51. PubMed ID: 21763505
[TBL] [Abstract][Full Text] [Related]
37. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
[TBL] [Abstract][Full Text] [Related]
39. miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27
Wang DD; Yang SJ; Chen X; Shen HY; Luo LJ; Zhang XH; Zhong SL; Zhao JH; Tang JH
Tumour Biol; 2016 Nov; 37(11):15315-15324. PubMed ID: 27699665
[TBL] [Abstract][Full Text] [Related]
40. Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway.
Park YH; Jung HH; Ahn JS; Im YH
Biochem Biophys Res Commun; 2013 Sep; 439(2):275-9. PubMed ID: 23973711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
